Table 1. Patient characteristics at the most recent follow-up visit.
Variables | Non-EIM group (n = 240) | EIM group (n = 31) | All cases (n = 271) |
---|---|---|---|
Sex (male/female) | 118/122 | 14/17 | 132/139 |
Age at diagnosis [year, median (IQR)] | 41.0 (28.0–53.0) | 47.0 (40.0–55.0) | 42.0 (29.0–53.3) |
Disease duration [year, median (IQR)] | 6.0 (4.0–10.0) | 14.0 (6.0–17.0) | 7.0 (4.0–10.0) |
Follow-up time [year, median (IQR)] | 13.0 (9.0–17.0) | 9.0 (6.0–13.0) | 13.0 (9.0–17.0) |
Relapse, n (%) | |||
First occurrence | 57 (23.8) | 6 (19.4) | 63 (23.2) |
First recurrence | 47 (19.6) | 2 (6.5) | 49 (18.1) |
Multiple recurrence | 136 (56.7) | 23 (74.2) | 159 (58.7) |
Stool with mucous, n (%) | 112 (46.7) | 21 (67.7) | 133 (49.1) |
Bloody stool, n (%) | 207 (86.3) | 25 (80.6) | 232 (85.6) |
Abdominal bloating and distension, n (%) | 48 (20.0) | 9 (29.0) | 57 (21.0) |
Diarrhea | 159 (66.3) | 28 (90.3) | 187 (69.0) |
Stool frequency, n (%) | |||
<4 times | 204 (85.0) | 18 (58.1) | 222 (81.9) |
≧4 time | 36 (15.0) | 13 (41.9) | 49 (18.1) |
Weight loss, n (%) | 86 (35.8) | 16 (51.6) | 102 (37.6) |
Extraintestinal manifestations (EIMs), n (%) | 31 (11.4) | 31 (11.4) | |
Single EIMs | 23 (8.4) | 23 (8.4) | |
Multiple EIMs | 8 (3.0) | 8 (3.0) | |
History of surgery, n (%) | 30 (12.5) | 7 (22.6) | 37 (13.7) |
Family history, n (%) | 15 (6.3) | 3 (9.7) | 18 (6.6) |
Family history of CRC | 3 (1.3) | 1 (3.2) | 4 (1.5) |
Family history of IBD | 2 (0.8) | 1 (3.2) | 3 (1.1) |
Family history of other caner | 12 (5.0) | 1 (3.2) | 13 (4.8) |
Extent of UC, n (%) | |||
E1 | 6 (2.5) | 0 (0.0) | 6 (2.2) |
E2 | 125 (52.1) | 16 (51.6) | 141 (52.0) |
E3 | 109 (45.4) | 15 (46.9) | 124 (45.8) |
Probiotics, n (%) | 84 (35.0) | 11 (35.5) | 95 (35.1) |
Steroids, n (%) | 148 (61.7) | 21 (67.7) | 169 (62.4) |
Immunomodulators, n (%) | 32 (13.3) | 2 (6.5) | 34 (12.5) |
Hb (g/L, mean ± SD) | 114.5 ± 25.1 | 109.7 ± 27.1 | 113.9 ± 25.3 |
ALT (g/L, mean ± SD) | 28.6 ± 23.1 | 24.7 ± 11.6 | 28.2 ± 22.1 |
Note:
CRC, colorectal cancer; UC, ulcerative colitis; IQR, interquartile range; Hb, hemoglobin; IBD, inflammatory bowel disease; Alb, Albumin.